ClinicalTrials.gg
RecruitingNCT06220773Updated Oct 16, 2026

A Study to Evaluate the Efficacy and Safety of BR1019A and BR1019B Combination Therapy

A Phase 3 interventional study of BR1019A and BR1019B in Essential Hypertension and Type 2 Diabetes Mellitus, sponsored by Boryung Pharmaceutical Co., Ltd. Recruiting at 3 sites in 2 countries. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Boryung Pharmaceutical Co., Ltd · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.
Updated Oct 16, 2026First site in IndonesiaPrimary completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
276
Allocation
Randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd — 8 open to participants now, 8 under way, 1 of them phase 3. Essential Hypertension · Boryung Pharmaceutical Co., Ltd.

Planned enrollment
3rd of 39
276 · median 58
Started
2024
with 4 others
Phase 3
11 of 44
1 open now
Registered
30th of 44
by date

Among the 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd, this one is the 3rd largest by planned enrollment of the 39 interventional ones that give a count, is one of 5 that started in 2024, is one of 11 in phase 3, and was the 30th registered.

Essential Hypertension

481 studies on the registry are indexed under Essential Hypertension; 77 are open to participants now.

Browse Essential Hypertension studies →

Open to participants now

8 of the 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd are open now, in 2 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 8 open studies →

Where they have run

Who these studies take

Of the 45 Essential Hypertension studies recruiting now, 17 (38%) set no upper age limit and 20 (44%) stop at 75 or younger; 4 take children under 18; 11 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Essential Hypertension by Boryung Pharmaceutical Co., Ltd, or all of them as a file.
02

Study summary

The objective of this clinical study is to Evaluate the Efficacy and Safety of BR1019A and BR1019B combination therapy in Patients with Essential Hypertension and Type 2 Diabetes Mellitus

03

Conditions studied

  • Essential Hypertension
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Those with type 2 diabetes mellitus \& essential hypertension
  • Those who agree to discontinue existing antihypertensive and/or oral hypoglycemic drugs during the clinical trial
  • Those who are judged medically reasonable by investigator to be able to discontinue existing antihypertensive and/or oral hypoglycemic drugs(except for Metformin) during the clinical trial

Exclusion criteria

Exclusion Criteria:

  • Those who meet the following criteria

    • Those with a history of secondary hypertension or suspected secondary hypertension; (Including but not limited to; e.g., renovascular disease, adrenal medullary and cortical hyperfunctions, coarctation of the aorta, primary hyperaldosteronism, unilateral or bilateral renal artery stenosis, Cushing's syndrome, pheochromocytoma and polycystic kidney disease, etc.)
    • Those with clinical significant orthostatic hypotension accompanied by symptoms
    • Those with diabetes mellitus taking renin inhibitors(Aliskiren) or moderate to severe renal impairment
    • Those with diabetic nephropathy taking ACE inhibitors
    • Those with type 1 diabetes mellitus, secondary diabetes mellitus, severe insulin-dependent diabetes, diabetic ketoacidosis or lactic acidosis
    • Those with uncontrolled, severe diabetic complications (Micro-vascular complications(e.g., nephropathy, retinopathy, neuropathy, etc.), Macro-vascular complications)
    • Diabetic coma or pre-coma
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
276 participants (estimated)

Study arms

  • Experimental
    BR1019A + BR1019B + BR1019C-1

    Drug: BR1019A · Drug: BR1019B · Drug: BR1019C-1

  • Active comparator
    BR1019A + BR1019B-1 + BR1019C-1

    Drug: BR1019A · Drug: BR1019B-1 · Drug: BR1019C-1

  • Active comparator
    BR1019A-1 + BR1019B + BR1019C-1

    Drug: BR1019B · Drug: BR1019A-1 · Drug: BR1019C-1

  • Other
    BR1019A-1 + BR1019B + BR1019C

    Drug: BR1019B · Drug: BR1019C · Drug: BR1019A-1

Interventions

  • DrugBR1019A

    Subjects take the investigational products once a day for 12 weeks.

  • DrugBR1019B

    Subjects take the investigational products once a day for 12 weeks.

  • DrugBR1019C

    Subjects take the investigational products once a day for 12 weeks.

  • DrugBR1019A-1

    Subjects take the investigational products once a day for 12 weeks.

  • DrugBR1019B-1

    Subjects take the investigational products once a day for 12 weeks.

  • DrugBR1019C-1

    Subjects take the investigational products once a day for 12 weeks.

06

What researchers measure

Primary outcomes

  1. The change of mean sitting systolic blood pressure from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A-1+BR1019B+BR1019C-1

    Time frame: 12 weeks from Baseline Visit

  2. The change of HbA1c from baseline in BR1019A+BR1019B+BR1019C-1 at Week 12 compared to BR1019A+BR1019B-1+BR1019C-1

    Time frame: 12 weeks from Baseline Visit

07

Study locations

3 of 3 sites recruiting
  • Rumah Sakit Jantung dan Pembuluh Darah Harapan Kita (RSJPD)
    Jakarta, DKI Jakarta 11420, Indonesia
    Recruiting
    • dr. Bambang Widyantoro, Sp.JP(K), PhD · Contactcru@pjnhk.go.id · (+62)21 1500034
  • Severance Hospital
    Seoul, South Korea
    Recruiting
    • Seok-min Kang, M.D., Ph.D. · Contact
  • Severance Hospital
    Seoul, South Korea
    Recruiting
    • Bong-Soo Cha, M.D., Ph.D. · Contact
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Dec 2026, 31 months after the start.

Of 45 industry-sponsored phase 3 interventional studies under Essential Hypertension, half reached primary completion within 16 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 24. This study's planned 31 months is above that.

Counting every sponsor, half of 47 studies reached it within 17 months; a quarter within 11 and three quarters within 24.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 16, 2026: primary completion Apr 2025 → Dec 2026 and completion Apr 2025 → Dec 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jan 14, 2024
First posted
Jan 24, 2024
StartActual
May 21, 2024
Primary completionEst.
Dec 2026was Apr 2025
CompletionEst.
Dec 2026was Apr 2025
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added — first site in Indonesia
Show site
  • Rumah Sakit Jantung dan Pembuluh Darah Harapan Kita (RSJPD) · Jakarta, Indonesia
Oct 16, 2026
Primary completion
Apr 2025→Dec 2026
Oct 16, 2026
Study completion
Apr 2025→Dec 2026
Oct 16, 2026
Show all 1 update
  1. Oct 16, 2026
    1 site added — first site in Indonesia
    Show site
    • Rumah Sakit Jantung dan Pembuluh Darah Harapan Kita (RSJPD) · Jakarta, Indonesia
    Primary completion Apr 2025→Dec 2026
    Study completion Apr 2025→Dec 2026
    + 2 other changes: verification date and index terms

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06220773
Responsible party
Sponsor
First posted
Jan 24, 2024
Start date
May 21, 2024
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Oct 16, 2026

Study contacts

Shin-young Oh
Contact
syoh@boryung.co.kr
+82-2-708-8000

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion